Best Genomics Companies in Seattle, United States
The 38 best Genomics companies in Seattle, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Shape Therapeutics.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Seattle
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Shape Therapeutics Developer of RNA-targeted therapies intended to treat multiple diseases | $148M | 61 mo ago | 117 | Prashant Mali Co-Founder | WordPress Block EditorWordPressMySQL+19 | 175 patents Engineering AAV vectors and guide RNAs for enhanced gene‑therapy delivery and expression. | 1 launch |
| 2 | CTI BioPharma Developer of targeted small molecule therapeutics for blood cancer | $132M | 110 mo ago | 25 | — | — | 64 patents Small-molecule therapeutics for FLT3-driven cancers, graft‑versus‑host disease, and viral infections | — |
| 3 | RareCyte Developer of technologies for the analysis of rare and single cells in the blood 60Funding top 24%Moat top 29%Patents top 32%Growth top 39% All 9 signals ▾Fundingtop 24% Moattop 29% Patentstop 32% Growthtop 39% Innovationtop 41% Markettop 47% Talentbottom 49% Globalbottom 40% Newsbottom 18% Funding: Raised $114M across 9 rounds · 9 rounds over 14 yrs (0.6/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 266 patents rank vs industry peers · Fliar Intelligence Index 60/100 | $114M | 15 mo ago | 54 54 → 61 (+13%) | Joseph Victor President & CEO | — | 266 patents Multiplexed fluorescence microscopy with spectral crosstalk reduction and angle-tuned illumination. | — |
| 4 | NanoString Developer of spatial biology tools for life sciences research | $108M | 78 mo ago | 652 | Dwayne Dunaway Co-Founder & Director | WordPress Block EditorWordPressApple iCloud Mail+25 | 340 patents Multiplexed in situ nucleic acid detection and spatial transcriptomics for cellular profiling | — |
| 5 | Parse Biosciences Developer of RNA-sequencing solution-based transcriptome kit to analyze health data | $100M | 33 mo ago | 107 | Geoff Krummel Co-Founder | WordPress Block EditorWordPressSentry+33 | — | 1 job opening · 1 launch |
| 6 | Cajal Neuroscience Developer of drugs for neurodegenerative disease based on genetic screening, and multi-omics approach | $96M | 45 mo ago | 60 | Ian Peikon Co-Founder | — | — | — |
| 7 | Twin Strand Bio Developer of DNA sequencing technology to identify genomic mutations | $84M | 18 mo ago | 70 | Mike Schmitt Co-Founder | WordPressPleskApple iCloud Mail+30 | — | — |
| 8 | Stratos Genomics Nanopore-based single molecule sequencer | $63M | 104 mo ago | 64 | — | — | 142 patents Improved polymerases and nanopore sequencing methods for high‑accuracy, high‑throughput DNA analysis | — |
| 9 | Arivale Provider of direct-to-consumer genetic testing. | $54M | 111 mo ago | 160 | — | — | 2 patents Predictive health analytics linking dynamic biomarkers to disease risk | — |
| 10 | Tune Therapeutics Developer of cell and gene therapy by using the epigenomic platform | $40M | 42 mo ago | 89 | Akira Matsuno Co-Founder | WordPress Block EditorWordPressMySQL+29 | — | — |
| 11 | Phytelligence Developer of disease-resistant plantlets and DNA sequencing services | $25M | 94 mo ago | 112 | — | — | — | — |
| 12 | ActX Provider of EHR integrated solutions to healthcare systems | $12M | 44 mo ago | 11 11 → 21 (+91%) | Andrew Ury CEO and Chairman | RubyUbuntuBootstrap+12 | 15 patents Cloud-based health data services and B‑cell mediated cell therapies for tissue regeneration | — |
| 13 | Synthesize Bio Provider of AI-generated gene expression data for biological research purposes | $10M | 11 mo ago | — | Robert Bradley Co-Founder | WebflowApple iCloud MailGSAP+13 | — | 1 launch |
| 14 | Myosana Therapeutics Developer of non-viral gene therapies for muscle disorders | $6M | 45 mo ago | 3 | Stan Froehner Co-Founder and Chairman of the Board | — | — | — |
| 15 | Phase Genomics Provider of laboratory and computational services and products | $6M | 16 mo ago | 19 19 → 14 (-26%) | — | — | 22 patents Genomic sequencing analytics, chromosome conformation capture, and lysin-based antibacterial therapeutics. | — |
| 16 | Geospiza Develops enterprise software systems for workflow management of genetic analysis | $5M | 188 mo ago | 1 | — | — | — | — |
| 17 | Spiral Genetics Provider of software to analyze next generation sequencing data | $4M | 90 mo ago | 8 | — | AMPCloudflareOpen Graph+1 | 30 patents Efficient compressed data indexing using prefix BWT and cloud-based sorting algorithms | — |
| 18 | Stemgenics Provider of stem cell technology that converts mature skin cells into stem cells | $3M | 98 mo ago | 5 | Andranik Andrew Aprikyan EVP | — | 50 patents Functionalized nanoparticles for intracellular gene delivery, editing, and cell reprogramming | — |
| 19 | Proteios Provider of protein technology solutions and drug discovery platform | $3M | 74 mo ago | 9 | — | — | — | — |
| 20 | adyn Provider of DNA and hormone analysis based birth control optimization kits | $3M | 64 mo ago | 10 | — | WordPressApple iCloud MailGoogle Workspace+27 | — | — |
| 21 | Onconome Blood test to assess risk of developing colorectal cancer | $2M | 190 mo ago | — | Ray Cairncross CEO | — | 7 patents Molecular diagnostic assays for colorectal cancer biomarker detection | — |
| 22 | Tend Manufacturer of microbiome cap device for medical treatment | $2M | 63 mo ago | 10 | Thomas Lendvay Co-Founder & Chief Medical Officer | — | — | — |
| 23 | ID Genomics Diagnostics for drug resistant infections. | $736K | 60 mo ago | 3 | — | — | 149 patents Clinical diagnostics using blood biomarkers for coronary disease and tissue sample analysis | — |
| 24 | Verda Bio Developer of cannabinoid genetics and ingredients for consumer product applications | $545K | 119 mo ago | 3 | Jessica Tonani Founder & CEO | — | — | — |
| 25 | Histone Therapeutics Developer of epigenetic reprogramming therapies for gene activation | $273K | 37 mo ago | — | Gregory Block Co-Founder & CEO | — | — | — |
| 26 | Attodx Developer of a pathogen detection technology for detecting viable bacterial pathogens | $183K | 137 mo ago | — | James Davie CEO | — | — | — |
Top 12 Genomics companies in Seattle
#1
Series C · Seattle, Washington · founded 2009 · 54 employees$114.3Mraised▾
Developer of technologies for the analysis of rare and single cells in the blood. The company's technologies enable convenient preparation and sophisticated multiparametric phenotypic analysis of rare cells including individual rare cell capture and retrieval for genomic analysis. Its technology platform has two integrated components AccuCyte (blood separation system) and CyteFinder (an instrument for cell imaging and analysis).
- May 2025Grant (prize money)$658.3K
- Jun 2024Series C$20M
- Jul 2023Series C$13.2M
- Sep 2021Series C$24M
#2
Series B · Seattle, Washington · founded 2015 · 70 employees$84Mraised▾
Developer of DNA sequencing technology to identify genomic mutations. It specializes in advanced DNA sequencing technologies, particularly proprietary Duplex Sequencing to identify genomic features that determine susceptibility to benzo pyrene-induced in vivo mutations.
- Feb 2025Grant (prize money)$5.7M
- Jun 2023Series B$10.3M
- May 2021Series B$50M
- Dec 2019Series A$16.3M
#3
Series A · Seattle, Washington · founded 2023$10Mraised▾
Provider of AI-generated gene expression data for biological research purposes. The company offers a platform enabling scientists to generate and analyze genomic data. It allows users to customize AI models, combine AI and experimental data, and visualize expression data. The platform supports molecular experiment design, synthetic control generation, and rare sample augmentation. It also facilitates data analysis, collaboration, and access to preprocessed public data.
- Sep 2025Series A$10M
#4
Series A · Seattle, Washington · founded 2015 · 19 employees$5.8Mraised▾
Provider of laboratory and computational services and products. The company has developed technology that allows the extraction of information regarding the physical proximity of DNA stretches inside the nucleus from short- or long-read HT sequencing allowing researchers to reconstruct the 3D organization of DNA within the nucleus. Phase Genomics' Proximo Hi-C measures the proximity of DNA in vivo and uses that information to scaffold contigs into entire chromosomes, or to deconvolute metagenomes from complex mixtures of environmental DNA.
- Apr 2025Grant (prize money)$299.2K
- Jan 2025Grant (prize money)$2M
- Mar 2024Grant (prize money)$1.5M
- Sep 2023Grant (prize money)$2M
#5
Series C · Seattle, Washington · founded 2018 · 107 employees$100.3Mraised▾
Developer of RNA-sequencing solution-based transcriptome kit to analyze health data. It offers solutions that empower researchers to run fixed samples collected on different dates together in a single experiment by providing control over sample handling and reducing errors. The kit uses barcoding to label single cells or single-nucleus suspension for sequencing as well as the tools for data analysis.
- Dec 2023Venture Debt—
- Dec 2023Series C$50M
- Feb 2022Series B$41.5M
- Jan 2021Series A$7M
#6
Series A · Seattle, Washington · founded 2020 · 60 employees$96Mraised▾
Developer of drugs for neurodegenerative disease based on genetic screening, and multi-omics approach. The company develops viral tools and platform to screen for the targets with functional impact on neurodegenerative disease progression. It also offers functional genetic screening, and multi-omics approaches to develop precision medicine for neurodegenerative disease.
- Nov 2022Series A$96M
#7
Series B · Seattle, Washington · founded 2009 · 89 employees$40Mraised▾
Developer of cell and gene therapy by using the epigenomic platform. The company has an epigenome editing and gene regulation platform to develop therapeutics for complex diseases without altering the DNA sequence.
- Mar 2023Series B$182.4M
- Dec 2021Series A$40M
#8
Series B · Seattle, Washington · founded 2018 · 117 employees$147.5Mraised▾
Developer of RNA-targeted therapies intended to treat multiple diseases. It provides platforms that includes a proprietary suppressor technology that permits premature stop codon readthrough, a precision RNA editing technology that uses endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform that generate tissue-tropic AAVs.
- Jul 2021Series B$112M
- Nov 2019Series A$35.5M
#9
Acquired · Seattle, Washington · founded 2003 · 652 employees$107.9Mraised▾
Developer of spatial biology tools for life sciences research. The company's portfolio includes the nCounter Analysis System for up to 800-plex direct digital detection of gene expression, the GeoMx Digital Spatial Profiler for whole transcriptome and protein profiling, and the CosMx Spatial Molecular Imager for single-cell imaging with subcellular resolution. The AtoMx Spatial Informatics Platform supports cloud-based analysis of spatial multiomics data.
- Mar 2020Post IPO$200M
- Jan 2020Grant (prize money)—
- Nov 2018Venture Debt$20M
- Oct 2018Conventional Debt$100M
#10
Acquired · Seattle, Washington · founded 1991 · 25 employees$132.4Mraised▾
Developer of targeted small molecule therapeutics for blood cancer. Their flagship product Pixantrone was granted conditional marketing approval in the EU, as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphomas. Other drugs in the pipeline are Pacritinib (myelofibrosis and relapsed acute myeloid leukemia), Tosedostat (relapsed acute myeloid leukemia and myelodysplastic syndrome), and Paclitaxel poliglumex (ovarian cancer).
- Jun 2017Post IPO$45M
- Dec 2013Venture Debt$5M
- Jan 2011Post IPO$25M
- Aug 2010Post IPO$4.6M
#11
Series B · Seattle, Washington · founded 2012 · 11 employees$11.8Mraised▾
Provider of EHR integrated solutions to healthcare systems. It helps physicians make better decisions about medical treatment, using a patient’s genetic information to guide therapy. Integrated into a physician’s normal software tools (the electronic medical record) and workflow, it analyzes the patient’s genetic information in real time and, for example, alerts the physician if a medication is unlikely to be effective or will cause side effects. It can also warn the physician about serious, actionable medical risks.
- Dec 2022Series B$6M
- Jul 2017Series A$3.1M
- Jul 2014Seed$750K
- Nov 2013Seed$1.9M
#12
Acquired · Seattle, Washington · founded 2007 · 64 employees$62.9Mraised▾
Stratos Genomics, a spin-off of Seattle-based Stratos Group is engaged in the development of a nanopore-based single molecule sequencer. The company's technology "Sequencing By Expansion (SBX)" allows conversion of DNA into an easily-read polymer or ‘xpandomer’, using a process similar to replication via polymerase. Further, it uses a modified polymerase which incorporates strings of four complementary bases called "Xprobes". The 4-base oligos, have four reporter molecules attached between the 2nd and 3rd base that helps in maintaining the normal steric properties of a 4-mer oligo. The xpandomer is melted off the template strand, expanding to 50-times the size of the original target DNA molecule and further threaded through a solid state nanopore which reads off the sequence as represented by the reporter molecules.
- Jan 2018Series B$20.2M
- Jun 2016Series B$4.5M
- Jun 2015Series B$30M
- Sep 2013Series A$2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Seattle researches in bioinformatics
- Seattle Children\'s Hospital11
- Seattle University9
- Seattle Reproductive Medicine2
- Seattle Cancer Care Alliance2
- Seattle Public Schools1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.